Syndax PharmaceuticalsSNDX
SNDX
About: Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
Employees: 184
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
56% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 25
38% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 60
7% more funds holding
Funds holding: 195 [Q2] → 209 (+14) [Q3]
1% more call options, than puts
Call options by funds: $15M | Put options by funds: $14.9M
0.32% more ownership
Funds ownership: 104.14% [Q2] → 104.45% (+0.32%) [Q3]
6% less capital invested
Capital invested by funds: $1.82B [Q2] → $1.71B (-$105M) [Q3]
18% less funds holding in top 10
Funds holding in top 10: 11 [Q2] → 9 (-2) [Q3]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$33
152%
upside
Avg. target
$41
212%
upside
High target
$51
290%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Edward White 24% 1-year accuracy 33 / 140 met price target | 290%upside $51 | Buy Reiterated | 10 Dec 2024 |
JP Morgan Anupam Rama 25% 1-year accuracy 15 / 59 met price target | 191%upside $38 | Overweight Maintained | 21 Nov 2024 |
Citigroup Yigal Nochomovitz 22% 1-year accuracy 10 / 46 met price target | 244%upside $45 | Buy Maintained | 19 Nov 2024 |
Goldman Sachs Chris Shibutani 36% 1-year accuracy 4 / 11 met price target | 152%upside $33 | Buy Maintained | 7 Nov 2024 |
UBS David Dai 18% 1-year accuracy 2 / 11 met price target | 183%upside $37 | Buy Initiated | 24 Oct 2024 |
Financial journalist opinion
Based on 5 articles about SNDX published over the past 30 days
Neutral
PRNewsWire
6 days ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK , Dec. 19, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX). If you are a shareholder of Syndax Pharmaceuticals, Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: https://pjlfirm.com/syndax-pharmaceuticals-inc/ You may also contact Robert H.
Neutral
PRNewsWire
2 weeks ago
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
– Subgroup analyses from Ph 2 protocol-defined R/R mNPM1 AML efficacy population (N=64) show responses across all major subgroups, including heavily pretreated patients – – 26% CR+CRh (20/77) and 48% ORR (37/77) in all enrolled patients who met the efficacy evaluable criteria in Ph 2 R/R mNPM1 AML cohort – – 100% ORR (37/37) and 95% CRc (35/37) in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT2Ar AML – – BEAT AML data highlight the potential for revumenib to advance the current standard of care – WALTHAM, Mass. , Dec. 9, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced additional positive data from the AUGMENT-101 trial of Revuforj® (revumenib) in relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) and the BEAT AML trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed AML patients.
Neutral
PRNewsWire
2 weeks ago
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
– 82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in combination with venetoclax and decitabine/cedazuridine in R/R AML – – 64% ORR (62 of 97 pts) and 23% CR/CRh (22 of 97 pts) with high rates of MRD negativity and ability to proceed to HSCT in expanded dataset of Ph 2 R/R KMT2Ar acute leukemia patients in AUGMENT-101 – – Responses were rapid, durable and observed across all major subgroups in expanded dataset ofPh 2 R/R KMT2Ar acute leukemia patients in AUGMENT-101 – – Latest data highlight the compelling clinical profile of revumenib and support advancement into combination trials in the frontline setting – WALTHAM, Mass. , Dec. 7, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today presented positive data from multiple trials of Revuforj® (revumenib) as a single-agent and in combination with standard of care agents in patients with acute leukemias in oral sessions at the 66th American Society of Hematology (ASH) Annual Meeting being held in San Diego, December 7-10, 2024.
Neutral
PRNewsWire
3 weeks ago
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass. , Dec. 3, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on December 1, 2024 the Company granted inducement awards to purchase up to 23,900 shares of common stock to two new employees under the Company's 2023 Inducement Plan.
Neutral
PRNewsWire
4 weeks ago
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference
WALTHAM, Mass. , Nov. 27, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A.
Positive
Reuters
1 month ago
US FDA approves Syndax's blood cancer drug
The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' drug for the treatment of adult and pediatric patients with a type of blood cancer, sending the company's shares up 3% in after-hours trading.
Neutral
PRNewsWire
1 month ago
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation – – Syndax to host conference call today at 6:00 p.m. ET – WALTHAM, Mass.
Positive
Seeking Alpha
1 month ago
Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity
Primary endpoint of pivotal phase 2 study met with statistical significance in using Revumenib for the treatment of relapsed/refractory mNPM1 AML patients; sNDA expected 1st half 2025. PDUFA action date of December 26th of 2024 deployed for FDA to decide if Revumenib should be approved for the treatment of relapsed/refractory KMT2Ar Acute leukemia patients. The global acute myeloid leukemia market is expected to reach $5.86 billion by 2030; About 10% of patients have KMT2Ar AML and then 30% have mNPM1 AML.
Neutral
PRNewsWire
1 month ago
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
– Primary endpoint met with CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R mNPM1 AML patients (p-value = 0.0014) – – 47% (30/64) ORR in a heavily pre-treated population, including 75% with prior venetoclax exposure in the efficacy population – – Favorable safety and tolerability profile; only 5% of patients discontinued due to treatment-related adverse events – – Results highlight consistency of revumenib's compelling clinical profile – – sNDA filing in R/R mNPM1 AML expected in 1H25, pending anticipated FDA approval of revumenib in R/R KMT2Ar acute leukemia in 4Q24 – – Syndax to host a conference call today at 8:00 am ET – WALTHAM, Mass. , Nov. 12, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced positive topline results from the relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) cohort in the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, an oral, small molecule menin inhibitor.
Neutral
Seeking Alpha
1 month ago
Syndax Pharmaceuticals, Inc. (SNDX) Q3 2024 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Neil Gallagher - President & Head, R&D Steve Closter - Chief Commercial Officer Keith Goldan - Chief Financial Officer Anjali Ganguli - Chief Strategy Officer Conference Call Participants Priyanka Grover - JPMorgan Brad Canino - Stifel Peter Lawson - Barclays Chris Shibutani - Goldman Sachs Kelly Shi - Jefferies Phil Nadeau - TD Cowen Michael Schmidt - Guggenheim Ashiq Mubarack - Citi Jason Zemansky - Bank of America George Farmer - Scotiabank Kalpit Patel - B. Riley Securities Justin Zelin - BTIG Operator Good day, everyone, and welcome to the Syndax Third Quarter 2024 Earnings Conference Call.
Charts implemented using Lightweight Charts™